In an analysis piece for Forbes, journalist Ed Silverman writes that the U.S. Food and Drug Administration may have used a flawed statistical model in its evaluation of the bleeding risks for the drug Pradaxa.
Pradaxa is a blood thinner, used to prevent blood clots and strokes in patients with atrial fibrillation. The Institute for Safe Medicine Practices has linked the drug to more than 500 deaths and ...
continue reading...